Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 8/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | TTR | P02766 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.40 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.40 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157893 | 1.00 | CXCL8 (0.49) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL6444552 | 1.00 | CXCL8 (0.49) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL6444559 | 1.00 | CXCL8 (0.49) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL6385877 | 0.89 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL6385872 | 0.89 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL5154999 | 0.79 | CXCL8 (0.48) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL5152429 | 0.79 | CXCL8 (0.48) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL5154990 | 0.79 | CXCL8 (0.48) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL5152439 | 0.79 | CXCL8 (0.48) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL9008056 | 0.79 | TTR (0.47) | CXCL8PTGS2TTRPTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060141044-A1 | Pharmaceutical compositions based on diclofenac derivate | NICOX S.A. (FR) | 2006-06-29 | — | — | US | claimed |
| US-20060122402-A1 | Manufacturing process for no-donating compounds such as no-donating diclofenac | NICOX SA (FR) | 2006-06-08 | — | — | US | claimed |
| EP-1558559-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | Nicox S.A. (FR) | 2005-08-03 | — | — | EP | claimed |
| WO-2004026808-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | NICOX SA. (FR) | 2004-04-01 | — | — | WO | claimed |
| US-20090170934-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | NICOX SA | 2009-07-02 | — | — | US | disclosed |
| US-20090096314-A1 | ELECTRIC MOTOR | HONDA MOTOR CO., LTD. (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20060141044-A1 | Pharmaceutical compositions based on diclofenac derivate | NICOX S.A. (FR) | 2006-06-29 | — | — | US | disclosed |
| US-20060141044-A1 | Pharmaceutical compositions based on diclofenac derivate | NICOX S.A. (FR) | 2006-06-29 | — | — | US | disclosed |
| US-20060122402-A1 | Manufacturing process for no-donating compounds such as no-donating diclofenac | NICOX SA (FR) | 2006-06-08 | — | — | US | disclosed |
| EP-1558559-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | Nicox S.A. (FR) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004026808-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | NICOX SA. (FR) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122402-A1 | Manufacturing process for no-donating compounds such as no-donating diclofenac | NOS2, NOS1, NOS3 | CXCL8 3224/4885PTGS2 30/4885TTR 2002/4885 |
| US-20090170934-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | NOS2, NOS1, NOS3 | CXCL8 3224/4885PTGS2 30/4885TTR 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.